Dr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market
November 14 2017 - 6:19AM
Business Wire
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE:
DRREDDY, NYSE: RDY) announced today that it has launched
Clofarabine Injection, a therapeutic equivalent generic version of
Clolar® (clofarabine) Injection in the United States market,
approved by the U.S. Food & Drug Administration (USFDA).
The Clolar® brand and generic had U.S. sales of
approximately $53 million MAT* for the most recent twelve months
ended in September 2017, according to IMS Health*.
Dr. Reddy’s Laboratories’ Clofarabine Injection
is available in single-dose, 20 mL flint vials containing 20 mg of
clofarabine in 20 mL of solution (1mg/mL).
Clolar® is a registered trademark of Genzyme
Corporation.
*IMS National Sales Perspective: Retail and
Non-Retail MAT September 2017RDY-0217-146
About Dr. Reddy’s: Dr. Reddy’s
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an
integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through
its three businesses - Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy’s operates in markets across
the globe. Our major markets include – USA, India, Russia & CIS
countries, and Europe. For more information, log on to:
www.drreddys.com
Disclaimer: This press release may
include statements of future expectations and other forward-looking
statements that are based on the management’s current views and
assumptions and involve known or unknown risks and uncertainties
that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In
addition to statements which are forward-looking by reason of
context, the words "may", "will", "should", "expects", "plans",
"intends", "anticipates", "believes", "estimates", "predicts",
"potential", or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events
may differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates ,
interest rates , persistency levels and frequency / severity of
insured loss events (ii) mortality and morbidity levels and trends,
(iii) changing levels of competition and general competitive
factors, (iv) changes in laws and regulations and in the policies
of central banks and/or governments, (v) the impact of acquisitions
or reorganization , including related integration issues.
The company assumes no obligation to update any
information contained herein
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171114005839/en/
INVESTOR RELATIONSSAUNAK SAVLA,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN PRINTER,
+91-40- 49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024